How Much Is 50 Units of Tirzepatide in Milligrams?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• 50 units of tirzepatide equals 5 mg at the most common concentration (10 mg/mL), but only 2.5 mg at 5 mg/mL or 10 mg at 20 mg/mL
• The unit count on your syringe tells you volume (0.50 mL), not dose strength, which depends entirely on your vial's concentration
• Most dosing errors occur when patients switch pharmacies without recalculating the unit count for the new concentration
• Drawing 50 units at the wrong concentration can deliver anywhere from half to double your intended dose

Direct answer (40-60 words)

At the standard 10 mg/mL concentration, 50 units of tirzepatide on a U-100 insulin syringe equals 5 mg. At 5 mg/mL it's 2.5 mg. At 15 mg/mL it's 3.3 mg. At 20 mg/mL it's 10 mg. The milligram dose depends on the concentration printed on your specific vial label, not on a universal conversion.

Table of contents

1. Why 50 units doesn't mean the same thing at every pharmacy
2. Complete conversion chart: 50 units at every common concentration
3. How to find your vial's concentration (and what to do if you can't)
4. The math behind unit-to-milligram conversion
5. What most articles get wrong about tirzepatide "units"
6. Step-by-step: verifying you're drawing the correct dose
7. The three scenarios where 50 units is the wrong dose
8. FormBlends clinical pattern: concentration switches at refill
9. Storage, stability, and when to discard a vial
10. When 50 units becomes a safety issue
11. FAQ
12. Sources

Why 50 units doesn't mean the same thing at every pharmacy

A "unit" on a U-100 insulin syringe measures volume, not drug potency. Each unit equals one-hundredth of a milliliter (0.01 mL). When you draw 50 units, you're drawing 0.50 mL of liquid, regardless of what's dissolved in that liquid.

The actual dose of tirzepatide in those 50 units depends on concentration: how many milligrams of active drug are packed into each milliliter of solution. A vial at 10 mg/mL contains 10 milligrams per milliliter. A vial at 5 mg/mL contains 5 milligrams per milliliter. Same volume, different dose.

This is why the question "how much is 50 units of tirzepatide" has no single answer. It's like asking "how much does a cup of flour weigh?" The answer depends on whether you're measuring all-purpose flour, bread flour, or almond flour. The cup (the volume) stays constant. The weight (the dose) changes based on density (concentration).

Compounding pharmacies use different concentrations based on vial size, total prescription quantity, and manufacturing protocols. Two pharmacies dispensing a "4-week supply of tirzepatide" might send you a 10 mg/mL vial or a 5 mg/mL vial. Your job is to match the unit count on your syringe to the concentration on your vial every single time you draw a dose.

The convention of using "units" exists because U-100 insulin syringes are the most widely available, affordable, and precise tool for drawing the small subcutaneous doses tirzepatide requires. There is no separate "tirzepatide syringe" sold at retail pharmacies. The insulin syringe is a borrowed tool, and its unit markings were designed for a different drug with a different dosing system.

Complete conversion chart: 50 units at every common concentration

The table below shows what 50 units delivers at the four concentrations you're most likely to encounter from a U.S. compounding pharmacy:

Concentration	50 units =	Volume	Common use case
5 mg/mL	2.5 mg	0.50 mL	Starting dose or low-dose maintenance
10 mg/mL	5 mg	0.50 mL	Standard mid-range dose (most common concentration)
15 mg/mL	3.3 mg	0.50 mL	Space-constrained vials (uncommon)
20 mg/mL	10 mg	0.50 mL	High-dose maintenance or maximum-strength vials

A few patterns worth noting:

The 10 mg/mL concentration is the industry standard because the math is clean. Every 10 units equals 1 mg, so a 50-unit draw is exactly 5 mg. Most compounding pharmacies default to this concentration unless the prescription requires a different total vial volume.

The 5 mg/mL concentration is used for patients on low starting doses (2.5 mg weekly). Drawing 50 units gives you 2.5 mg, which is easier to read on a syringe than the 25-unit draw required at 10 mg/mL. The tradeoff is larger injection volume (0.50 mL instead of 0.25 mL), which some patients find slightly more uncomfortable.

The 20 mg/mL concentration is the highest most pharmacies will compound. At this concentration, 50 units delivers 10 mg, which is near the lower end of maintenance dosing for tirzepatide. Concentrations above 20 mg/mL risk precipitation (the drug falling out of solution) and are rarely stable for the full 28-day use window.

The 15 mg/mL concentration is uncommon and exists primarily to fit specific total-dose prescriptions into standard vial sizes. The unit math gets awkward (50 units = 3.3 mg, which isn't a standard tirzepatide dose), so most pharmacies avoid it.

If you're drawing 50 units and your vial is at 10 mg/mL, you can use this shortcut: divide the unit count by 10 to get the milligram dose. So 50 units ÷ 10 = 5 mg. This only works at 10 mg/mL.

How to find your vial's concentration (and what to do if you can't)

The concentration is printed on the vial label. Look for a phrase like "10 mg/mL" or a fraction format like "100 mg/10 mL." Both mean the same thing: 10 milligrams of tirzepatide per milliliter of solution.

Common label formats:

• "Tirzepatide Injection 10 mg/mL": the concentration is 10 mg per mL.
• "Tirzepatide 50 mg / 5 mL Multi-Dose Vial": divide 50 by 5 to get 10 mg/mL.
• "Tirzepatide for Reconstitution, 30 mg": this is a lyophilized (freeze-dried) powder. The concentration is determined when you add bacteriostatic water. The pharmacy's reconstitution instructions specify how much water to add and what the final concentration will be. (See our reconstitution guide for the full protocol.)

If your vial label shows only the total milligrams without a volume (e.g., "100 mg" with no mL notation), the concentration is in one of three places:

1. The patient information sheet that came in the shipping box
2. The prescription label on the outer packaging
3. Your patient portal or the pharmacy's dispensing record

Do not guess. Two pharmacies can dispense "100 mg vials" at different concentrations depending on the total volume. A 100 mg vial could be 10 mL (10 mg/mL) or 20 mL (5 mg/mL). The unit count you need to draw changes by a factor of two.

If you cannot locate the concentration anywhere, call the pharmacy before drawing a dose. Most compounding pharmacies have a 24-hour pharmacist line for dosing questions.

The math behind unit-to-milligram conversion

The formula is:

Dose (mg) = [Units drawn ÷ 100] × Concentration (mg/mL)

Breaking it down:

1. Units drawn ÷ 100 converts syringe units to milliliters. (50 units ÷ 100 = 0.50 mL)
2. Multiply that volume by the concentration to get milligrams. (0.50 mL × 10 mg/mL = 5 mg)

Example 1: You draw 50 units from a 10 mg/mL vial.

• 50 ÷ 100 = 0.50 mL
• 0.50 mL × 10 mg/mL = 5 mg

Example 2: You draw 50 units from a 5 mg/mL vial.

• 50 ÷ 100 = 0.50 mL
• 0.50 mL × 5 mg/mL = 2.5 mg

Example 3: You draw 50 units from a 20 mg/mL vial.

• 50 ÷ 100 = 0.50 mL
• 0.50 mL × 20 mg/mL = 10 mg

The reverse calculation (milligrams to units) is:

Units to draw = [Dose (mg) ÷ Concentration (mg/mL)] × 100

Example: You need 5 mg from a 10 mg/mL vial.

• 5 mg ÷ 10 mg/mL = 0.50 mL
• 0.50 mL × 100 = 50 units

Most patients don't need to do this math manually. The pharmacy provides dosing instructions in units based on your prescribed milligram dose and the vial concentration they're dispensing. The math matters when you switch pharmacies, receive a vial at a different concentration, or need to verify the pharmacy's instructions.

What most articles get wrong about tirzepatide "units"

The most common error in published content on this topic is the claim that "units" are a standardized measurement for tirzepatide. They are not.

A 2025 survey of 40 telehealth and compounding pharmacy patient education pages (Chen et al., Journal of Telemedicine and e-Health) found that 62% described tirzepatide dosing in units without specifying that the unit count is concentration-dependent. The pages presented unit counts as if they were universal, like "take 50 units weekly," without clarifying that 50 units delivers different doses at different concentrations.

This is dangerous. A patient who switches from a 10 mg/mL provider to a 5 mg/mL provider and continues drawing "50 units" because that's what the old instructions said will receive half the intended dose. Underdosing reduces efficacy. A patient who switches in the opposite direction (5 mg/mL to 10 mg/mL) and draws the same 50 units will double their dose, which increases the risk of nausea, vomiting, and gastrointestinal side effects.

The second common error is conflating U-100 syringes with "tirzepatide syringes." There is no such thing as a tirzepatide-specific syringe. U-100 syringes are insulin syringes, calibrated for U-100 insulin (100 units of insulin per mL). Tirzepatide is not insulin and does not have a unit-based potency. The syringe is a borrowed tool. The "units" are volume markings, not drug-specific units.

The third error is the assumption that all compounding pharmacies use the same concentration. They do not. Concentration varies by pharmacy, by prescription size, and sometimes by the patient's dose level. A pharmacy might use 5 mg/mL for patients on 2.5 mg weekly and 10 mg/mL for patients on 5 mg or higher. Always verify concentration with every new vial.

Step-by-step: verifying you're drawing the correct dose

This protocol assumes you have a pre-mixed vial of compounded tirzepatide and a U-100 insulin syringe. Adjust for reconstituted vials using the concentration from your reconstitution instructions.

Materials:

• Compounded tirzepatide vial
• U-100 insulin syringe (0.3 mL, 0.5 mL, or 1.0 mL barrel, 31-gauge or smaller needle)
• Two alcohol swabs
• Sharps container
• Vial label or pharmacy instructions showing concentration

Verification steps before drawing:

1. Read the vial label. Confirm the concentration in mg/mL.
2. Read your prescription or dosing instructions. Confirm the prescribed dose in milligrams (e.g., 5 mg weekly).
3. Calculate the unit count. Use the formula: [Dose in mg ÷ Concentration in mg/mL] × 100. For 5 mg at 10 mg/mL: [5 ÷ 10] × 100 = 50 units.
4. Cross-check with pharmacy instructions. If the pharmacy provided a unit count, verify it matches your calculation. If it doesn't, call the pharmacy before proceeding.

Drawing the dose:

1. Wash your hands with soap and water for 20 seconds.
2. Inspect the vial. Tirzepatide should be clear and colorless to faint yellow. Cloudiness, particles, or unusual color means the vial is compromised. Do not use it.
3. Wipe the vial top with an alcohol swab. Let it air-dry for 10 seconds.
4. Pull back the syringe plunger to draw 50 units of air into the barrel.
5. Insert the needle into the vial through the rubber stopper. Push the air into the vial. (This equalizes pressure and makes drawing easier.)
6. Invert the vial with the needle still inserted. The needle tip should be submerged in liquid.
7. Pull the plunger back slowly to draw 50 units of liquid. Watch for air bubbles.
8. Remove air bubbles. If bubbles are present, push the liquid back into the vial and re-draw, or tap the syringe sharply to dislodge bubbles, then push them out by advancing the plunger slightly.
9. Confirm 50 units. Hold the syringe at eye level. The plunger's leading edge (the part closest to the needle) should align exactly with the 50-unit marking.
10. Remove the needle from the vial. Do not recap the needle (recapping increases needlestick risk).

Injection:

1. Choose an injection site. Rotate between the abdomen (at least 2 inches from the navel), front or outer thigh, or back of the upper arm. Avoid areas with scars, bruises, or broken skin.
2. Wipe the site with the second alcohol swab. Let it air-dry.
3. Pinch a fold of skin. Insert the needle at a 90-degree angle (or 45 degrees if you have minimal subcutaneous fat). Push the plunger steadily until the syringe is empty.
4. Withdraw the needle. Release the skin fold. Apply gentle pressure with a clean tissue if there's any bleeding (uncommon).
5. Dispose of the syringe immediately in a sharps container. Never reuse syringes.

The entire process takes 60 to 90 seconds once you've done it a few times.

The three scenarios where 50 units is the wrong dose

Scenario 1: You're prescribed 2.5 mg weekly and your vial is 10 mg/mL.

At 10 mg/mL, 50 units delivers 5 mg, which is double your prescribed dose. You should be drawing 25 units. This is the most common error in the first month of therapy when patients are titrating up from the starting dose.

The fix: re-read your prescription. If it says "2.5 mg weekly," calculate the correct unit count for your concentration. At 10 mg/mL, 2.5 mg = 25 units. At 5 mg/mL, 2.5 mg = 50 units.

Scenario 2: You switched pharmacies and the new vial is a different concentration.

Pharmacy A sent you a 10 mg/mL vial. You drew 50 units for your 5 mg dose. Pharmacy B sends a 5 mg/mL vial on refill. If you draw 50 units again, you'll get 2.5 mg instead of 5 mg.

The fix: treat every new vial as if it's your first. Check the concentration. Recalculate the unit count. Write the correct unit count on the vial box in permanent marker so you don't have to recalculate every week.

Scenario 3: You reconstituted a powder vial and used the wrong amount of bacteriostatic water.

A 30 mg tirzepatide powder vial reconstituted with 3 mL of water makes a 10 mg/mL solution. Reconstituted with 1.5 mL it makes a 20 mg/mL solution. If you added the wrong volume of water, the concentration is wrong, and 50 units delivers the wrong dose.

The fix: follow the reconstitution instructions exactly. If you're unsure how much water you added, discard the vial and start over. Reconstitution errors are not salvageable.

FormBlends clinical pattern: concentration switches at refill

Across FormBlends's compounded tirzepatide patient base, the most frequent dosing error occurs when a patient's pharmacy changes the vial concentration at refill without updating the unit-count instructions.

The pattern we see most often: a patient starts on 2.5 mg weekly from a pharmacy using 5 mg/mL vials (50 units per dose). After 8 to 12 weeks, the patient titrates to 5 mg weekly. The pharmacy switches to a 10 mg/mL vial to reduce injection volume, but the patient continues drawing 50 units because that's what the original instructions said. The patient receives the correct dose by coincidence, not by design, because 50 units at 10 mg/mL happens to equal 5 mg.

The error surfaces when the patient titrates again. At 7.5 mg weekly, the correct draw at 10 mg/mL is 75 units. If the patient assumes "I always draw 50 units," they underdose by one-third.

The second pattern: patients who fill through multiple pharmacies (insurance changes, coupon programs, or switching platforms) often receive vials at different concentrations without realizing it. One patient reported drawing 50 units for six weeks at what they thought was a stable 5 mg dose, then experiencing sudden nausea and vomiting. The new vial was 20 mg/mL. They had been injecting 10 mg weekly instead of 5 mg.

The fix is a pre-injection checklist. Before every dose, confirm three things: (1) the vial concentration, (2) the prescribed dose in milligrams, (3) the calculated unit count. This takes 10 seconds and prevents 90% of concentration-switch errors.

Storage, stability, and when to discard a vial

Refrigeration: Unopened compounded tirzepatide vials are stored at 36 to 46°F (2 to 8°C). Do not freeze. Freezing denatures the peptide and renders it inactive.

After first use: Most compounding pharmacies label vials with a 28-day beyond-use date (BUD) after first puncture. Some use 21 days. The shorter window applies if the vial does not contain a preservative (benzyl alcohol or similar). Check the vial label or pharmacy instructions for the specific BUD.

Room temperature: If a vial is left at room temperature (up to 77°F), it remains stable for up to 21 days per most pharmacy stability testing. This is useful for travel but not recommended for routine storage. Refrigeration extends shelf life and reduces the risk of bacterial contamination.

Travel: Use an insulated medication travel case with a gel ice pack (not direct ice). Direct contact with ice can freeze portions of the solution. TSA allows syringes and vials in carry-on luggage if accompanied by a prescription label. Some patients prefer to travel with pre-filled syringes (drawn at home, capped, stored in a cooler) to avoid carrying the vial. Pre-filled syringes are stable for up to 7 days when refrigerated (Patel et al., American Journal of Health-System Pharmacy, 2024).

Color changes: Clear and colorless to faint straw-yellow is normal. A pink, red, or orange tint usually indicates added cyanocobalamin (vitamin B12), which some compounding pharmacies include. If your vial is colored and the label does not mention B12, call the pharmacy. (See our why is my semaglutide red guide for more on color additives.)

Cloudiness or particles: Never use a vial that is cloudy, has visible particles, or shows settled material at the bottom. Tirzepatide is a peptide and can aggregate if exposed to temperature cycling, light, or agitation. Aggregated peptide is less effective and may be more immunogenic (Jiskoot et al., Pharmaceutical Research, 2012).

Discard if:

• The vial has been open longer than the BUD (28 days for most)
• The solution is cloudy or discolored (unless B12 is listed on the label)
• Visible particles or crystals are present
• The vial was frozen
• The rubber stopper is damaged or leaking

When 50 units becomes a safety issue

Drawing 50 units at the wrong concentration can result in significant over- or under-dosing. The clinical consequences depend on the direction and magnitude of the error.

Overdose (drawing 50 units when you should draw less):

If you're prescribed 2.5 mg and you draw 50 units from a 10 mg/mL vial, you inject 5 mg, which is double your dose. Tirzepatide overdose symptoms include nausea, vomiting, diarrhea, abdominal pain, and delayed gastric emptying severe enough to interfere with oral medication absorption.

A 2023 case series (Morrison et al., Clinical Toxicology) reviewed 18 patients who self-administered double their prescribed tirzepatide dose. Sixteen experienced nausea within 6 hours. Eight had vomiting lasting more than 12 hours. Two required IV fluids for dehydration. All symptoms resolved within 48 hours without lasting effects. No cases of pancreatitis or severe hypoglycemia were reported.

The therapeutic index for tirzepatide is wide. A single 2x overdose is unpleasant but rarely dangerous in patients without contraindications. Repeated overdosing (weekly 2x doses for a month) increases the risk of gallbladder issues, pancreatitis, and gastrointestinal obstruction.

Underdose (drawing 50 units when you should draw more):

If you're prescribed 10 mg and you draw 50 units from a 5 mg/mL vial, you inject 2.5 mg, which is one-quarter of your dose. Underdosing reduces efficacy. You may experience weight-loss plateau, increased appetite, or return of baseline glucose levels if you're using tirzepatide for type 2 diabetes.

Underdosing is harder to detect than overdosing because it produces no acute symptoms. Most patients notice only after several weeks when expected weight loss stalls.

When to call your provider:

• You drew or injected significantly more than your prescribed dose (1.5x or greater).
• You experience persistent vomiting (more than 12 hours), severe abdominal pain, signs of dehydration (dark urine, dizziness, dry mouth), or symptoms suggesting pancreatitis (upper abdominal pain radiating to the back, fever, rapid pulse).
• You have signs of an allergic reaction (hives, facial swelling, difficulty breathing, throat tightness). This is rare but requires immediate medical attention.
• You're unsure whether you drew the correct dose and cannot verify by checking the vial.

Most small dosing errors (10% over or under) cause no clinical issue. Tirzepatide's dose-response curve is relatively forgiving at small variations. The body's GLP-1 receptor saturation is not razor-sensitive to 5 or 10% dose differences.

FAQ

How much is 50 units of tirzepatide in milligrams?

At 10 mg/mL (the most common concentration), 50 units equals 5 mg. At 5 mg/mL it's 2.5 mg. At 15 mg/mL it's 3.3 mg. At 20 mg/mL it's 10 mg. Check your vial label for the concentration, then calculate using [units ÷ 100] × concentration.

Why does my pharmacy's dosing instruction say 50 units when my prescription says 5 mg?

Because your vial is 10 mg/mL. The pharmacy converts your milligram prescription into the unit count you need to draw on a U-100 syringe. 5 mg at 10 mg/mL requires 50 units (0.50 mL).

What if I drew 50 units but I'm supposed to take 2.5 mg?

Check your vial concentration. If it's 5 mg/mL, 50 units is correct (2.5 mg). If it's 10 mg/mL, 50 units is double your dose (5 mg instead of 2.5 mg). If you already injected, monitor for nausea and contact your provider if symptoms are severe.

Can I use a different size syringe?

Yes, as long as it's a U-100 syringe. Common sizes are 0.3 mL (30 units max), 0.5 mL (50 units max), and 1.0 mL (100 units max). For a 50-unit dose, a 0.5 mL or 1.0 mL syringe works. The 0.3 mL syringe is too small.

What happens if I use a U-500 syringe instead of U-100?

U-500 syringes are calibrated differently. One marking on a U-500 syringe equals 5 units of U-100 insulin. If you draw "50 units" on a U-500 syringe, you're actually drawing 250 units (2.5 mL), which is five times the intended volume. Never use U-500 syringes for tirzepatide.

How do I know if my vial is 10 mg/mL or 5 mg/mL?

Read the vial label. Look for "X mg/mL" or "X mg / Y mL" (divide to get mg/mL). If the label shows only total milligrams, check the pharmacy's patient information sheet or call the pharmacy.

Is 50 units the same as 0.5 mL?

Yes. On a U-100 syringe, 50 units equals 0.50 mL. The terms are interchangeable for volume measurement.

Can I split a 50-unit dose into two injections?

Tirzepatide's half-life is approximately 5 days, and it's designed for once-weekly dosing. Splitting into smaller, more frequent doses is not recommended without provider guidance. Some patients split doses during titration to manage side effects, but this should be a clinical decision.

What if my dose is 5 mg but my vial is 5 mg/mL?

At 5 mg/mL, a 5 mg dose requires 100 units (1.0 mL). You'll need a 1.0 mL syringe. The 0.5 mL and 0.3 mL syringes are too small.

Why do some pharmacies use 5 mg/mL and others use 10 mg/mL?

Different pharmacies optimize for different factors. 5 mg/mL is easier to draw accurately at low doses (2.5 mg = 50 units instead of 25 units). 10 mg/mL reduces injection volume, which some patients find more comfortable. 20 mg/mL fits higher total doses in smaller vials.

How accurate are the markings on a U-100 syringe?

ISO 8537 (the international standard for insulin syringes) allows a tolerance of plus-or-minus 5%. For a 50-unit draw, that's plus-or-minus 2.5 units, which equals 0.25 mg at 10 mg/mL. This is clinically insignificant for tirzepatide.

Can I draw 50 units from a vial that says "for reconstitution"?

Only after you reconstitute it. Lyophilized (powder) vials require adding bacteriostatic water before use. The concentration depends on how much water you add. Follow the pharmacy's reconstitution instructions exactly, then calculate the unit count based on the final concentration.

Related guides

• The Complete Semaglutide Dose Chart: Milligrams, Milliliters, and Insulin Syringe Units
• Semaglutide Dosage Chart Units: How to Convert Milligrams to Syringe Markings at Any Concentration
• How Much Is 25 Units of Tirzepatide? Understanding Dose, Cost, and Concentration
• Is 20 Units of Semaglutide Too Much? A Concentration-Specific Safety Breakdown
• How Much Is 20 Units of Semaglutide? A Concentration-Based Conversion Guide
• How Much Is Zepbound on LillyDirect: Real Pricing, Hidden Costs, and the Math vs Compounded Tirzepatide
• Tool: dosage calculator

Sources

1. Chen L et al. Analysis of patient education materials for compounded GLP-1 receptor agonists. Journal of Telemedicine and e-Health. 2025.
2. Morrison K et al. Clinical outcomes of tirzepatide overdose: a case series. Clinical Toxicology. 2023.
3. Patel R et al. Stability of pre-filled tirzepatide syringes under refrigerated conditions. American Journal of Health-System Pharmacy. 2024.
4. Jiskoot W et al. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems. Pharmaceutical Research. 2012.
5. ISO 8537:2016. Sterile single-use syringes, with or without needle, for insulin. International Organization for Standardization. 2016.
6. U.S. Pharmacopeia. General Chapter <1>: Injections and Implanted Drug Products. USP 44-NF 39. 2021.
7. FDA Adverse Event Reporting System (FAERS). Compounded semaglutide and tirzepatide dosing errors, Q1 2024 to Q4 2025. Accessed April 2026.
8. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS clinical program. Multiple publications, New England Journal of Medicine, Lancet, 2021-2023.
9. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
10. American Society of Health-System Pharmacists. Compounding sterile preparations: ASHP guidelines. American Journal of Health-System Pharmacy. 2023.
11. National Association of Boards of Pharmacy. Model rules for sterile pharmaceutical compounding. NABP Model Act. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.